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Abstract
Health-related stigma remains a major barrier to improving health and well-being for vulnerable populations around
the world. This collection on stigma research and global health emerged largely as a result of a 2017 meeting on the
“The Science of Stigma Reduction” sponsored by the US National Institutes of Health (NIH). An overwhelming
consensus at the meeting was reached. It was determined that for stigma research to advance further, particularly to
achieve effective and scalable stigma reduction interventions, the discipline of stigma research must evolve beyond
disease-specific investigations and frameworks and move toward more unified theories of stigma that transcend
individual conditions. This introduction reflects on the value of taking this cross-cutting approach from both a historical
and current perspective, then briefly summarizes the span of articles. Collectively, the authors apply theory, frameworks,
tools, interventions and evaluations to the breadth of stigma across conditions and vulnerabilities. They present a
tactical argument for a more ethical, participatory, applied and transdisciplinary line of attack on health-related stigma,
alongside promoting the dignity and voice of people living with stigmatized conditions. The collection homepage can
be found at http://www.biomedcentral.com/collections/stigma.
Introduction
The constitution of the World Health Organization in-
cludes the principle that “the enjoyment of the highest
attainable standard of health is one of the fundamental
rights of every human being without distinction of race,
religion, political belief, economic or social condition
[1].” Evidence shows that, globally, stigma is key in gen-
erating and perpetuating health inequities, despite the
medical advances that make improved health possible
[2] by deterring care-seeking and otherwise undermining
individuals’ capacity to receive available care. Import-
antly, when care provision for stigmatized conditions is
de-prioritized and/or overtly ignored, stigma also under-
mines investments in health. Consequently, there have
been escalating calls to reduce stigma to promote health
equity in a variety of disease contexts, including epilepsy
[3], HIV [4], and mental illness [5]. This special collec-
tion of articles responds to these calls by articulating
cross-cutting approaches to health-related stigma re-
search and interventions in low and middle income
countries (LMICs). It builds on an international effort to
discuss the etiology and impact of stigma across condi-
tions on the health of global citizens, while considering
the methods and interventions that could be harnessed
to measure and address stigma.
In recent decades, researchers have studied the risk
factors and prevalence of health-related stigma, as well
as how to measure stigma within certain disease con-
texts and populations, such as HIV, mental health and
substance use. However, eliminating discrimination in
healthcare settings requires time-bound targets and tar-
geted funds, with resources allocated to programs and
actions that are proven to work. The continually evolv-
ing burden of disease poses new challenges for the de-
velopment of such interventions, with the added
complexity that individuals may be affected by multiple
stigmatized conditions, and/or potentially belong to stig-
matized populations.* Correspondence: GBond@zambart.org.zm
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To date, most research to address health-related
stigma has occurred within disease silos. Yet, theorists
have highlighted significant similarities in the drivers,
manifestations, and outcomes of stigma across health
conditions [6]. Some researchers have also suggested
that common approaches may be used to measure and
intervene in stigma across health conditions [6, 7]. We
are clearly at a tipping point in stigma research. New
models for intervention research, novel approaches for
studying intersectional stigma, and nimble research
frameworks, which can be applied across different dis-
ease contexts, are needed if we are to make real headway
in combatting some of the world’s most stubborn health
problems. This special collection reflects the progress
made in stigma research to date, as well as the evolving
global health landscape and shifting disease burdens.
Communities are now better poised than ever to actively
partner in research, and increasingly, researchers
recognize that interventions must be developed, evalu-
ated, and implemented in collaboration with community
members to be effective and sustainable [8].
Given the unfinished agenda of eliminating stigma to
ensure health for all (particularly in LMICs), the rising
burden of chronic, non-communicable diseases, and the
fact that people with HIV are living longer and facing mul-
tiple stigmatizing conditions, there has been renewed
interest in confronting health-related stigma in the global
health context. This collection reflects the research chal-
lenges, priorities and opportunities addressed during the
workshop, to catalyze new research approaches and col-
laborations and move this critical field forward.
Progression of stigma theory: a historical perspective
A conclusion of the 2017 NIH meeting was that under-
standing stigma theory was critical for anti-stigma en-
deavors (for a brief summary of the progression of
stigma theory, see Fig. 1). However, all too often, theory
is either missing from endeavors or too heavily present
to be useful beyond an academic network. Stigma theory
emerged after World War 2, at a time when social sci-
ence interest was “more in social theory than social pol-
icy or health policy [9],” and focused on the process of
labeling and stigmatizing. This body of theory was devel-
oped in social science, pivoting around management of
an identity affected by a “discrediting [10]” attribute and
the concept of “deviance [11].” Both attributes and the
“deviance” label were shown to endorse social norms
and solidarity by labeling difference as a flaw, and as so-
cially unacceptable. This leads to social exclusion and
what Goffman termed “a spoiled identity [10].”
Unsurprisingly, the concept of “deviance” is now consid-
ered objectionable – not least because it overlooks the role
of power [12]. Labeling, however, explicitly makes the link
with power by exposing how social control and social
Fig. 1 Progression of stigma theory, adapted from Weiss, 2008 [9]
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construction drive fear about certain groups. Link and
Phelan [13] break down the social process of stigma
around labeling. First, ‘difference’ is identified and labeled,
then a labeled person is linked to undesirable characteris-
tics, followed by group labeling that separates “them” from
“us”. The stigmatized group (“them”) subsequently experi-
ences discrimination and loss of status. Power is exercised
to reinforce this separation [13].
Inherent in labeling is the subsequent denial of civil
rights, making stigma a human rights issue [9]. This rec-
ognition marked the shift from the academics of struc-
tural and social processes to considering psychological,
health and behavioral outcomes and how stigma is expe-
rienced [14]. Tyler and Slater elaborate that, “redefining
stigma has taken place NOT in sociology but in social
psychology, medical and health research and, to lesser
extent, law and criminology [15].” It became obvious
that to really understand and resist stigma, consideration
of the wider context and the political economy of
stigmatization was needed [16]. As Deacon stated,
“stigma is more than just an injury to an individual, but
an indicator of the health of the social environment
[17].” This includes what Deacon labels “the social land-
scape of prejudice [17].” Jonathan Mann, a key figure in
advocating for HIV funding, called the sociopolitical re-
sponse – including discrimination against HIV – the
“third epidemic”, with the first epidemic being the
spread of HIV and the second being AIDS as a disease.
He recognized that meaningful and sustained social
change against stigma will not occur unless social classi-
fication is challenged and social justice is pursued [15].
In the history of stigma theory, there are useful core
concepts for health-related stigma. Jones et al. identified
six dimensions of health conditions that could make
them more or less stigmatized: concealability (hidden/
visible), course of condition (and anticipated social con-
sequences, disruptiveness (impact on social interactivity),
aesthetic qualities (signs and symbols), origin (etiology
and perceived blame), and peril (social danger). Key ex-
periences of stigma were identified as devaluation, exclu-
sion, and disadvantage [18]. The most common types of
stigma are anticipated stigma (stigma that you fear may
occur), enacted stigma (actions that occur against a per-
son because of stigma) and internalized stigma (that
which causes the individual to feel less of a person and
“shame becomes a central possibility [10].” Each condi-
tion has both specific stigma features and the capacity to
deepen stigma of another health condition.
Goffman closes his seminal book with an appeal for
different disciplines to work together across stigma-
tised conditions. “Knowing what fields like race rela-
tions, aging and mental health share,” he urges us to
examine the similarities and differences between a
variety of disciplines [10]. It is only then, he claims,
that we can come up with a “coherent analytic per-
spective”. This approach, called for more than 50
years ago, underlies this special collection.
An overview of this collection on Stigma Research and
Global Health
Each of the nine contributions in this collection on
Stigma Research and Global Health offers stand-alone
value, yet together they provide a comprehensive and
complementary perspective on this important topic. A
critical and shared perspective across the contributions
is that to move toward meaningful and scalable inter-
ventions, stigma research must expand beyond the limi-
tations inherent in addressing stigma associated with a
single condition, to develop and embrace a unified or
generic theory of its drivers and mechanisms, measure-
ments for stigma and stigma interventions that tran-
scends any individual stigmatized condition or identity.
In “Out of the silos: identifying cross-cutting features
of health-related stigma to advance measurement and
interventions,” van Brakel et al. [19] argue that their
generic approach to stigma offers important opportun-
ities for cross-cutting, synergistic research that will likely
also be more cost-effective than investments in
single-condition stigma reduction efforts. In “The
Health, Stigma and Discrimination Framework,” Stangl
et al. [20] take this idea even further by providing a glo-
bal, cross-cutting framework to guide research, interven-
tion development and policy on health-related stigma.
Their framework is based upon theory, research and
practice, and they offer illustrations of the framework
applied across numerous conditions. Importantly, Stangl
et al. note that identifying commonalities in the stigma
process across conditions will amplify our collective abil-
ity to respond and scale-up. In “Challenges and oppor-
tunities in examining and addressing intersectional
stigma and health”, Turan et al. [21] address the conver-
gence of multiple stigmatized identities. Though it is
clearly a common phenomenon when individuals with
health-related stigma are viewed holistically rather than
through a single-condition lens, to date, little research
has been undertaken on this complex convergence.
Turan et al. review the existing data, detail methodo-
logical gaps in the study of intersectional stigma, and
suggest priority areas for future research to advance the
field. In the context of intersectional stigma work, they
also discuss the possibility that stigmatized individuals
may gain resiliency and improved health and wellbeing
through the solidarity of their own communities.
Three insightful systematic reviews offer further reve-
lations about the present state of stigma research, and
shine a light on priority areas for future study. In “A sys-
tematic review of multilevel stigma interventions: state
of the science and future directions,” Rao et al. [22]
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identified 24 published examples of multilevel interven-
tions, which mainly used an educational approach at the
interpersonal and intrapersonal levels. They call for
more rigorous study designs to address this gap. In “Im-
plementation science and stigma reduction interventions
in low and middle income countries: a systematic re-
view” Kemp et al. [23] report on 35 published studies of
evaluations of stigma reduction interventions in LMICs
that offered at least one implementation outcome. They
found that most of these studies examined acceptability
and feasibility, none took a transdiagnostic approach to
decrease stigma across multiple health conditions, and
few included conceptual Implementation Sciences
frameworks. They conclude that studies evaluating
adoption, appropriateness, cost, fidelity, penetration and
sustainability are needed, as well as more granular de-
tails of interventions. In “A scoping review of
health-related stigma outcomes for high burden diseases
in LMICs”, Kane et al. [24] explore HIV, mental illness, tu-
berculosis, epilepsy and substance abuse research. Their
aim was to highlight commonalities across these condi-
tions, including key moderators and mediators of stigma
and health, and identify vulnerable and at-risk groups.
The systematic reviews in this collection are comple-
mented by an Opinion piece on participatory research,
and a Correspondence article on stigma in health facil-
ities. Sprague et al. [25] articulate the imperative for par-
ticipatory praxis, with an emphasis on the need for a
shared starting point from the strengths and assets of
the community. This would avoid further objectification,
and rather enhance agency, dignitary and wellbeing,
while also producing work that is more relevant, reliable
and valid. This contribution recognizes the challenges in
conducting participatory work, noting that, “for
community-engaged practice to become more than an
ethical aspiration, structural changes in funding, train-
ing, publishing and tenure processes will be necessary.”
In the Correspondence article, “Stigma in health
facilities: why it matters and how we can change it,”
Nyblade et. al [26] provide a case study in which this
cross-cutting approach has been applied to tackle stigma
in healthcare facilities. They review the literature on
stigma reduction strategies in health facilities, while also
exploring the potential for facility-based strategies to
occur across multiple conditions.
Conclusion
As well as reviewing recent developments in research,
theory, and intervention in health-related stigma in
LMICs, this collection of articles provides a roadmap for
researchers, healthcare providers, policymakers, commu-
nity members, and other key stakeholders, to address
the issue of stigma to enhance global health equity. Key
guideposts on this roadmap include first deconstructing
the silos that have, to date, stifled a fluid exchange of
findings and innovations across disease contexts. Cata-
lyzing cross-cutting approaches to research, theory, and
intervention has the potential to spur more rapid and ef-
ficacious solutions to health-related stigma. Secondly, to
understand and address this complex, multilevel social
phenomenon, it is crictical to build transdisciplinary
scientific teams. Solutions to health-related stigma will
require expertise from public health, medicine, psych-
ology, sociology, and anthropology, as well as other sci-
entific disciplines. Thirdly, it is critical to partner with
community members, providers, policymakers, and
other stakeholders, to ensure that research and interven-
tions are responsive, feasible, and efficacious. It is only
through working together – across disease silos, disci-
plines, and scientist–community member boundaries –
that we will be able to effectively address health-related
stigma and enhance global health equity.
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